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ABSTRACT
Medication nonadherence and lack of transition readiness are global challenges for
individuals living with epilepsy and their families. Medication adherence measures the level of
compliance with healthcare providers' treatment recommendations. Transition readiness is the
gradual steps patients take to develop independence and self-management as they transfer from
pediatric to adult healthcare models. Factors impacting medication adherence and transition
readiness skills include developmental stage/age; forgetfulness; family/caregivers;
socioeconomic status; knowledge/attitude about the disease; side effects; number of medications;
and subjective and objective quantifications of adherence. One promising intervention for
patients and families is mobile technology used for reaching, teaching, and communicating.
However, no study has tested how mobile applications (m-apps) effect both medication
adherence and transition readiness. This four-week study's primary aim was to test Medilepsy's
(an m-app) effect on medication adherence in adolescents and young adults with epilepsy
(AYA), ages 16-24, with and without caregiver support. Secondary aims were to examine
Medilepsy's effect on transition readiness skills and evaluate usability, ease of use, and
satisfaction. A one-group, quasi-experimental pre-post study design was used. A repeated
measures test analyzed changes in medication adherence at five times. A Wilcoxon test analyzed
mean pre-post transition readiness scores. There was no significant improvement in medication
adherence mean scores. Significant improvement was demonstrated in self-reported pre-post
transition readiness mean scores, with greatest improvement in two domains: Appointment
Keeping by 13.75% and Managing Medications by 11.25%. The highest usability mean scores
were 6.09 of 7 in ease of use, interface, and satisfaction. Participants scored Medilepsy 82.3% of
100%. This study contributes to chronic disease self-management science illustrating how
iii

Medilepsy reaches and engages AYA and caregivers. Future studies will expand the Medilepsy
platform and include different research designs, longer study durations, younger and more
diverse participants.
Keywords: adolescents, epilepsy, medication adherence, mobile app, transition readiness,
young adults.
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CHAPTER ONE: INTRODUCTION
In the United States, 470,000 children and adolescents live with epilepsy, with over
150,000 newly diagnosed cases each year.1 Epilepsy is a common and chronic neurological
disease often associated with unprovoked seizures greater than 24 hours apart or one unprovoked
seizure with a probability of reoccurrence within ten years.2,3 Comorbidities and symptoms of
epilepsy can include anxiety, depression, mood disorders, and cognitive impairments. 2,3 The
primary treatment for epilepsy is antiepileptic drugs (AED), which do not cure epilepsy but help
control seizures.5 Scholars report that "70% of patients respond to AEDs whereas 30% do not."4,5
Medication adherence is the congruence level or percentage to which patients' behavior
complies with providers' treatment recommendations, including taking prescribed medications.5
Nonadherence is 30% or greater in adolescents and young adults with epilepsy (referred to as
AYA from this point forward).5 Negative consequences of nonadherence can include:
exacerbation of seizures, avoidable hospitalization costs (> $100 billion per annum), and in some
cases, lead to death.4,6 Research shows that AYA who have difficulty with medication adherence
may experience difficulty with transition readiness skills.7,8 Transition readiness skills refer to
AYAs gradual independence in managing their epilepsy, including medication adherence, selfadvocacy, competent healthcare decisions, and a successful transfer of care from a pediatric
model to an adult model of health care, which is often a complex and a challenging process.7-9
Overview of Chapter Two: Influencing Factors and Measures of Medication Adherence
in Adolescent and Young Adults with Epilepsy: An Integrative Literature Review
In this review, the focus was to investigate the primary aim of this research study: factors
that influence medication adherence in AYA. Factors that influence medication adherence were
classified into two categories: patient-related factors and therapy-related factors. Patient-related
1

factors included developmental stage/age, forgetfulness, family conflict, caregiver burden, and
knowledge/attitude about disease.4,8,10 Therapy-related factors included the number of
medications and side effects such as gastrointestinal difficulties or drowsiness.
Types of medication adherence measures were also examined. Subjective measures
included the Morisky Medication Adherence Scale (MMAS), Beliefs about Medicines
Questionnaire (BMQ), Pediatric Epilepsy Medication Self-Management Questionnaire
(PEMSQ), Pediatric Epilepsy Side Effect Questionnaire (PESQ), and Adolescent Epilepsy
Medication Self-Management Questionnaire (AEMSQ). Objective measures included an
electronic pill monitoring system, text messaging, and a mobile application (m-app). The review
revealed a low number of studies with tools validated to measure medication adherence. Further,
studies did not stratify data by age intervals (e.g., 10-12, 13-17, 18-21 years), which poses
challenges to designing developmentally appropriate interventions that could improve
medication adherence for AYA. Thus, a combination of subjective and objective measures would
likely be a more robust methodology for assessment, leading to the development of betterinformed interventions for this vulnerable population.
Overview of Chapter Three: The Effect of the Medilepsy Mobile App Intervention
on Medication Adherence and Transition Readiness in Adolescents and
Young Adults with Epilepsy: A Quasi-Experimental Study
The purpose of this four-week study was to test the effect of a novel iPhone Medilepsy
mobile application (m-app) in AYAs (ages 16-24) with and without caregiver support. The
primary aim was to examine Medilepsy's effect on medication adherence. Secondary aims were
to examine Medilepsy's effect on transition readiness skills and evaluate Medilepsy's usability
per participants' feedback on a questionnaire. Participants included 31 AYAs from 16 states
(mean age 20.9 years; females, 73.3%, Caucasian, 93.3%, and college-educated, 76.6%). This
2

study consisted of mostly younger adults (93.3%) with no caregiver support. Before the study,
participants self-reported AED medication adherence. This was calculated as the number of
missed medication doses for seven days by the number of doses prescribed per week and
recorded by the Primary Investigator (PI) as the pre-medication adherence rate (AR) score.
Participants also completed the following surveys: Transition Readiness Assessment
Questionnaire (TRAQ),11 a validated tool using a 5-point Likert scale to measure transition
readiness,11 and the mHealth App Usability Questionnaire (MAUQ),12 a validated tool using a 7point Likert scale to measure m-app usability in the domains of Ease of Use, Interface, and
Satisfaction, and Usefulness. An admin panel created for Medilepsy tracked medication entries
weekly during the four-week study. The age span of 16-24 years was selected for this study
because the only validated tool on the market to measure transition readiness was the TRAQ.11
Chapter Three also provides a comprehensive description of the development of
Medilepsy, along with supplemental illustrations. Each phase of the study is presented, and
results, limitations, and future directions are discussed. This study contributes to the science of
chronic disease self-management because it demonstrates the ability of an m-app, Medilepsy, to
reach and engage AYA and caregivers. As newer app versions are piloted, Medilepsy may show
greater promise as a reliable resource for educating AYA and caregivers, healthcare providers,
and the epilepsy community about the disease to improve medication adherence and transition
readiness. Future studies should include working with skilled technicians in research settings and
expanding the Medilepsy platform to consist of different research designs and longer study
durations, including younger participants and underrepresented groups.
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Theoretical Framework
The Revised Self-Management and Family Management Framework (RSFM), which
encompasses the science of self-management, was chosen as an appropriate framework to guide
this study.13 The RSFM focuses on understanding the complexities of chronic diseases in the
context of facilitators and barriers, processes, and proximal and distal outcomes. This model
highlights how facilitators and barriers can influence self-management, such as aspects of one's
personal/lifestyle and health status.13 The Personal/Lifestyle category involves knowledge,
beliefs, emotions, and life patterns.13 In contrast, the RFSM describes Health Status as
comorbidities, cognitive functioning, symptoms, and medication side effects.14 Processes target
skills and strategies to manage chronic disease.13 These processes incorporate three main factors:
1) Focusing on Illness Needs, which involves learning, taking ownership of healthcare needs,
and engaging in health-promoting activities,13 2) Activating Resources involves patients and
families coordinating healthcare services, communicating with providers, and managing
spiritual, psychological, social, and community needs and challenges,13 3) Living with the
condition refers to patients and families coping with their disease, processing emotions, making
adjustments and trying to manage their disease within activities of daily life parameters.13
Proximal Outcomes involve modifying cognitions and adherence behaviors in persons diagnosed
with a chronic disease.13 Distal Outcomes, which extend beyond the scope of this study, include
Health Status (control, mortality, morbidity) and Individual and Family Outcomes (quality of life
and function).13

4

Overview of Chapter Four: A Novice Researcher's Recruitment Challenges and
Lessons Learned From a Mobile Application Interventional Study:
Adolescents and Young Adults with Epilepsy.
Recruitment of participants diagnosed with a chronic disease/condition for Research
interventional studies can be demanding and time-consuming.14-15 In this chapter, challenges, and
lessons of a novice researcher's recruitment efforts are highlighted in two main areas: 1)
recruitment methods during a pandemic and 2) the importance of rapport and communication
with participants, healthcare providers, and organizations that support research. The most
impactful lesson learned was that researchers should strive to place themselves in participants'
shoes and ask themselves, "Would I sign this consent?" Researchers' collaboration with their
respective IRBs in adapting consent language is warranted. Chapter Four adds to the limited
body of literature on recruitment methods for healthcare research with AYA. In the spirit of
advancing the science of self-management for young patients and families coping with chronic
disease, other new investigators are encouraged to share their recruitment challenges and
potential solutions.
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CHAPTER TWO: INFLUENCING FACTORS AND MEASURES OF MEDICATION
ADHERENCE IN ADOLESCENTS AND YOUNG ADULTS WITH EPILEPSY: AN
INTEGRATIVE LITERATURE REVIEW
Abstract
Although epilepsy research is broad and comprehensive, medication adherence among
adolescents and young adults with epilepsy (AYA) is not well studied. Nonadherence in
adolescents and young adults with epilepsy is 30% or greater, which can result in exacerbated
seizures, emergency room visits, hospitalizations, increased healthcare costs, and in some cases,
mortality. Despite the severity of these outcomes, little is known about factors that influence
medication adherence in AYA ages 10-24 or adherence measures used with them. The purpose
of this integrated literature review is to advance the science of epilepsy by exploring, classifying,
and synthesizing available research about medication adherence in AYA.
The following databases were consulted: APA PsycInfo, MEDLINE, and CINAHL Plus
with Full Text. To examine relatively current research, only studies published from January 2010
through September 2020 were included in this review.
Seven studies from three countries met inclusion criteria. Influencing factors related to
adherence in AYA were classified into patient-related factors and therapy-related factors.
Patient-related factors included developmental stage/age, forgetfulness, family issues, caregiver
burden, and knowledge/attitude about disease. Therapy-related factors included the number of
medications and side effects. Types of medication adherence measures were also examined.
Subjective measures included Morisky Medication Adherence Scale (MMAS), Beliefs about
Medicines Questionnaire (BMQ), Pediatric Epilepsy Medication Self-Management
Questionnaire (PEMSQ), Pediatric Epilepsy Side Effect Questionnaire (PESQ), and Adolescent
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Epilepsy Medication Self-Management Questionnaire (AEMSQ). Objective measures included
an electronic pill monitoring system, text messaging, and a mobile application (m-app).
A systematic method for categorizing factors that influence medication adherence among
AYA may help standardize adherence protocols and may reduce the risks of seizures, medication
side effects, costs associated with hospitalizations, and mortality. A robust assessment approach
that employs both subjective and objective measures validated and stratified by age intervals
would better inform the development of interventions for this vulnerable population.
Keywords: adolescents, caregivers, epilepsy, integrative review, measurements/tools,
medication adherence, non-compliance
Background
Medication adherence is the congruence or percentage level to which patients' behavior
complies with providers' treatment recommendations, including taking prescribed medications.1-3
According to the Centers for Disease Control and Prevention, 470,000 children and adolescents
live with epilepsy, with over 150,000 new cases each year.4 Epilepsy is a common, chronic
neurological disease characterized by two unprovoked seizures greater than 24 hours apart or one
unprovoked seizure with a probability of reoccurrence within ten years.5, 6 Comorbidities and
symptoms of epilepsy can include anxiety, depression, mood disorders, and cognitive
impairments. 4-5 The primary treatment for epilepsy is antiepileptic drugs (AED), which do not
cure epilepsy but help control seizures.5,6 Scholars report that "70% of patients respond to AEDs,
whereas 30% do not." 1,6 Nonadherence in adolescents and young adults with epilepsy (referred
to as AYA from this point forward) is 30% or greater, which can result in exacerbation of
seizures, avoidable hospitalization costs of more than $100 billion annually, and in some cases,
loss of life.1,7-9
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In a systematic review of the literature, roughly 771 reasons for medication nonadherence
among the general population were reported.9 Reasons for nonadherence were primarily
categorized into six factors (patient-related, socioeconomic-related, condition-related, therapyrelated, measurement-related, and healthcare system-related). Studies including caregivers, who
can significantly influence adherence, typically lacked important details, such as type (eg, nurses,
immediate or extended family members, friends, and neighbors. None of these studies included
patients with epilepsy,9, so little is known about factors influencing medication adherence in
AYA between 10 and 24 years.2-3, 9,11 Further, studies revealed a confusing array of different
assessment measures,11 and many studies did not stratify data by age intervals (eg, 10-12, 13-17),
which pose challenges to designing developmentally appropriate interventions to improve
adherence among specific age groups.
Methods
Search Terminology
The research team agreed upon the following search terms: [(MH "Epilepsy") OR (MH
"Seizures") OR (MH "Convulsions") or convulsion* or seizure* or epilep*) AND ((MH
"Anticonvulsants+") or medication* or anticonvulsant* or "seizure drug therapy" or "epilepsy
drug therapy" or (MH "Epilepsy/DT") or (MH "Seizures/DT")) AND ((MH "Medication
Compliance") or complian* or adheren* or nonadheren* or concordance or noncomplian* or
non-concordance ) AND ((MH "Adolescence") or adolescent* or "young people" or teen* or
youth* or "young adult*" or child*)].
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Databases Consulted
A systematic search was conducted using the search terms and the following databases:
APA PsycInfo, MEDLINE, and CINAHL Plus with Full Text. The same procedure was used for
each search to ensure that search terms complied with every database. The search included all
relevant studies published from January 2010 through September 2020 (Figure 1).

Figure 1. PRISMA Flow Diagram
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Study Selection
The following inclusion criteria was used: research studies in English that reported on
adolescents aged 10-24 with epilepsy in outpatient settings, factors that could influence
medication adherence, and studies with interventions or surveys that measured medication
adherence. Exclusion criteria included research studies not available in full text, dissertations,
and studies not published in peer-reviewed or scholarly journals. Studies were also excluded if
they included diagnostic testing and surgical interventions (eg, hospitalized patients,
electroencephalograms [EEG], vagal nerve stimulators [VNS]), and specific antiepileptic drug
(AED) protocols.
Level of Evidence and Quality Assessment
Article level of evidence (Table 1) was determined with the assessment criteria published
in Melnyk and Fineout-Overholt (eg, critically appraising evidence, the role of outcomes and
evidence-based quality improvement, etc.).12 Measurement instrument quality level was assessed
with the John Hopkins Nursing Evidence-Based Research Appraisal Tool12,-13 and the criteria
published in Holmbeck and Devine.14
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Table 1. Medication Adherence Studies Involving AYA
Author(s),
Year
Gabr &
Shams,1
2015

Study
Design
Crosssectional

Modi et al.,2 Pilot RCT
2016

Level of
Measurement of
Evidence
Medication
and Quality
Adherence
Level IV
Morisky
Quality: B
Medication
Adherence Scale
(MAS) and
Beliefs about
medicines
Questionnaire
(BMQ).

Level II
Quality: B

MEMS ™ or
SimpleMed Textmessaging and/or
an applicationbased reminder
(MEMS ™ or
SimpleMed)
intervention.
Background
questionnaire.
Chart review

Sample and Data Collection

N=116, AWE 13-18 years (14.96±1.74).
n=94 completers.
Medication Adherence (MA) was measured by
MAS (4 items re feelings taking medicines,
range, 0-4). Score of >1 = low adherent.
And two sections of BMQ: measuring beliefs
about medicines in general and a specified
medicine. Five-point Likert scale. Higher
scores are indicative of stronger beliefs
represented by the scale.

General Findings Related to Factors

On the MAS, 38.3% or 36 AWE subjects were
non-adherent.
Patient-related: Forgetfulness was the most
common reason
Social and economic-related:
Size of family, mother's age (p<0.05), stability
of the family, and family support (p<0.01).
Beliefs/culture (8.4% of non-adherent patients
believed evil demons possessed them.)
Therapy-related: number of prescribed
medicines (p<0.05), fear from side-effects.
Condition-related: severity of disease/complex
treatments.
N=25 AWE (mean age, 15.7) and caregivers. Text-messaging and application-based
Duration of study: 30 days. Baseline
reminders are feasible for short durations.
demographic/clinical information was
Factors that Influence MA:
collected from the questionnaire and chart. All Patient-related: Addresses forgetfulness short
subjects received MEMS ™ or SimpleMed
term
(microchip registers date and time medicine
Group 2 (text-messaging for AWE and parent)
cap or pill compartment are opened, which
had significantly higher adherence at the
sends data wirelessly to a secured website.
beginning of intervention (p<0.005), Group 1
Subjects randomized to 1 of 5 interventions
(texting for AWE) showed a trend toward
Group 1) AWE text-only, Group 2) AWE and higher adherence at the beginning of
caregiver text plus single-family
intervention (p=0.075).
communication (verifying via text instead of AWE and parent dynamics: AWE and
asking the AWE about taking medicine to
parents receiving text messages, or an
reduce conflict and nagging), Group 3) AWE adherence application showed decreased
application only, Group 4) Application for
adherence over time (p=0.10). It may be due to
AWE and caregiver plus single-family
AWE and parent conflict.
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Author(s),
Year

Study
Design

Level of
Evidence
and Quality

Carbone et
al., 3 2013

Crosssectional

Level IV
Quality: C

Smith et al.,
15
2018

Longitudinal Level III
Study
Quality: B

Measurement of
Medication
Adherence

The Pediatric
Epilepsy
Medication SelfManagement
Questionnaire
(PEMSQ)
The Adolescent
Epilepsy
Medication SelfManagement
Questionnaire
(AEMSQ)

Sample and Data Collection

communication, and Group 5 (control group)
epilepsy tool-kit application for AWE only.
Adherence data collection: MEMS ™ or
SimpleMed
N=88 AWE 12-17 years and parents completed
surveys. Self-reported scores were analyzed,
and outcomes were reported.

General Findings Related to Factors

Measurement-related: Electronic adherence
data is feasible to measure adherence.
However, observation of swallowing is not
confirmed objectively.
Factors that Influence MA:
Patient-related: Providing AWE and
caregivers knowledge on epilepsy and
treatment plans may improve adherence. AWE
who self-reported better epilepsy knowledge
showed higher adherence and was correlated
with parent self-reported adherence scores
(p<0.001). There was discordance in scale
scores for every parent-AWE pair, which
predicted lower adherence (p<0.001).
Parents consistently scored higher in epilepsy
knowledge and treatment adherence compared
to their AWE. Fewer siblings (p=0.003)
predicted higher adherence.
Therapy-related: More medications predicted
lower adherence (p=0.042).
N=48 AWE (mean age 14.8 years ±1.5) and
Baseline adherence of 86% declined over 12
caregivers. n=48 completers.
months (p<0.001). Adherence dropped by 2%
Study duration: 12 months. Subjects attended 4 every month. AWE missed one in 4 doses of
study visits (every 3-4 months). Subjects
their AED on average by the end of the study.
completed pre, during, and post surveys about Factors that Influence MA:
health-related quality of life, epilepsy
Patient-related: Greater epilepsy knowledge
knowledge, medication adherence, beliefs
can promote adherence.
about medication efficacy, and side effects.
Forgetfulness/memory problems.
During each visit, MEMS ™ data was
Lower family conflict and higher family
downloaded to analyze medication adherence support predict higher adherence (p<0.05).
and PRO. Daily MA was averaged for each
Social and economic related: Higher SES
predicted higher adherence (p<0.05).
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Author(s),
Year

LeMarne et
al.,16
2018

Study
Design

Mixed
Methods

Hixon &
Review
17
Braverman Article
2019

Level of
Evidence
and Quality

Measurement of
Medication
Adherence

Level IV
Quality: B

M-app/EpApp
Parent logbook
Adolescent
Knowledge of
Epilepsy
Questionnaire
(AKEQ)

Level IV
Quality B

Reviewed 14
digital tools

Sample and Data Collection

General Findings Related to Factors

Therapy-related: fewer side effects (p<0.01).
Missed Refills=barrier
Measurement-related: Surveys alone may not
be able to measure the multitude of reasons
that impact adherence. Use of randomization
stratification so that groups have equal baseline
adherence rates at the start of the study. MEMS
™ is a feasible intervention but cannot confirm
if pills were taken.
N=51AWE subjects 13-19 years (14.49) and
AWE MA improved with medication
parent.
reminders via m-app
n=36 completers. Study duration: one month. during study, (p=0.002) and after follow-up,
MA was measured by the number of
(p=0.03).
medication reminders the AWE received via
Factors that Influence MA:
m-app and
Patient-related: education/AKEQ improved
by parent daily log of AWE adherence.
adherence (p<0.005). AWE playing an active
Frequency counts of page visits via m-app.
role and have a lower conflict with a parent can
Interview post-intervention w/ all subjects.
improve MA.
Measurement-related: data measured in realtime and secured stored as well as parent
oversight.
Wearables, digital diaries, web-based peer
Patient education programs about epilepsy
support networks, epilepsy, and SM programs. management included learning about
medications that target attitudes and selfefficacy and improve MA.
Factors that Influence MA:
Patient-related: M-apps targeted forgetfulness
and running out of medicines with
reminders/alert features. Healthcare beliefs:
through online counseling and peer-support
groups, and education sessions.
month =12 months. MA= number of doses
taken/number of expected doses x100%.
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Author(s),
Year

Escoffery
et al.18
2018

Study
Design

Review
Article

Level of
Evidence
and Quality

Level IV
Quality: B

Measurement of
Medication
Adherence

Sample and Data Collection

General Findings Related to Factors

Therapy-related: Education on the proper use
of medication, dealing with medication side
effects.
Social-economic: M-apps may reduce
healthcare provider visits through electronic
communication, reduce running out of
medications (electronic refilling), and boost
health literacy
Measurement-related: Keeping track of MA
and side effects using an m-app/digital
platform can help promote self-efficacy and
may improve MA.

AWE MA improved with medication
reminders via m-app during the study
(p=0.002) and after follow-up (p=0.03).
Factors that Influence MA:
Patient-related: education/AKEQ improved
adherence (p<0.005). AWE playing an active
role and have a lower conflict with the parent
can improve MA.
Measurement-related: data measured in realtime and secured stored as well as parent
oversight.
Reviewed 20 m- M-apps targeted: medication adherence
7 out of the 20 m-apps were geared for
apps. MARS,
(medication reminders, prompts/cues).
adolescents/children that may be beneficial for
behavioral change, Education/Support: web platforms specific for medication adherence and SM:
and selfpersons with epilepsy.
Young Epilepsy
management
Seizure Sync
reported
Epilepsy Tool Kit
epilepsy/seizure
EpiDiary
education, seizure
Epilepsy Health Storylines
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Author(s),
Year

Study
Design

Level of
Evidence
and Quality

Measurement of
Medication
Adherence
management, and
medication
adherence.

Sample and Data Collection

General Findings Related to Factors

Epi and Me 2 Handme
Cleveland Clinic MyEpilepsy app
Factors that Influence MA:
Patient-related: M-apps targeted:
forgetfulness, promote self-efficacy and timemanagement, improve knowledge, provide
social support.
Therapy-related: Track medicines, side effects, refill medications.
Measurement-related: Tracks and records
MA in real-time. Keep records of MA and
epilepsy to share with the provider.
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Data Extraction
The initial search was conducted by the first author and in consultation with a librarian.
Articles and citations were identified and uploaded into an online reference manager library.
Both authors were involved in six phases of the literature review: (1) identification of
biographical search criteria and databases, (2) abstract and title assessment, (3) full article
review, (4) organization of final citations into categories, (5) identification of factors influencing
medication adherence, and (6) appraisal of studies that employed self-management tools per
Holmbeck and Devine's checklist of criteria14 (Table 2). Both authors discussed and achieved
congruent views regarding every phase of article selection, data extraction, level of evidence, and
quality assessment.
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Table 2. Criteria for Measures Development
Instrument

Scientific

Content

Need

Validity

Reliability

Quantitative

Factor

Item Analysis

Analysis

Validity Clinical
Utility

Cost-

Translated

effectiveness

to Other
Languages

Subjective
MMAS

+

+

+

+

+

+

+

-

+

BMQ

+

+

+

+

+

+

+

-

+

PEMSQ

+

+

+

+

+

+

+

-

-

PESQ

+

+

+

+

+

+

+

-

-

AEMSQ

+

-

-

-

-

-

-

-

-

MEMS ™

+

+

+

+

+

+

+

-

-

Text-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

-

+

+

+

+

+

+

+

+

+

Objective

messaging
MEMS ™
and PESQ
MEMS ™
and PESQ
M-app
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Search Results
The initial search produced 656 articles from peer-reviewed and scholarly journals. Hand
searches of articles identified five additional articles. After removal of duplicates, 508 articles
remained, from which 454 were excluded, leaving 54 for eligibility review. Of these, 47 did not
meet inclusion criteria. The most common reasons for exclusion included: (1) subjects' ages were
≤ than 10 years or ≧25 years, (2) wrong diagnosis and other medical conditions (eg, cancer,

congenital diseases, viral infections, cortical malformations), (3) no specific methods used to
measure medication adherence, and (4) inpatient settings. A total of seven studies were thus
retained for this review (Figure 1, PRISMA).
Results
Study characteristics are summarized in Table 1. Sample sizes ranged from 25-94
participants, aged 12-19 years. Five studies were conducted in the United States, one in
Australia, and one in Saudi Arabia. Study designs included one pilot randomized controlled trial,
one longitudinal cohort study, two cross-sectional studies, one mixed-methods study, and two
review articles.1-3, 15-18 Factors related to medication adherence in AYA were classified into

patient-related factors and therapy-related factors. Measurements were classified into subjective
measures (e.g., questionnaires) and objective measures (e.g., electronic pill monitoring system,
mobile application). In studies employing a combination of subjective and objective measures,
findings were mixed.
Patient-related Factors
Patient-related factors comprised developmental stage / age, forgetfulness, family /
caregivers, and knowledge / attitude about disease.
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Developmental Stage/Age
In four studies, adolescence was reported as a challenging time for AYA as they strive for
autonmony.1- 2, 15-16 Poor execution of tasks is not uncommon. In this regard, AYA may
experience the following: cognitive deficits and learning disorders, lack of motivation, increased
peer pressure due to stigma, and teen-caregiver conflict.1-2, 15-16 In two studies, age of diagnosis
was considered a possible predictor of medication adherence since some adolescents were
diagnosed at a young age and may not have received training or strategies to manage
medications because caregivers typically fulfilled that role.2, 15 In one study of AYA and family
members, however, no significant association was found between AYA age and medication
adherence (p=0.74), but the age of adolescents' mothers was significantly correlated with
nonadherence (p < 0.05).
Forgetfulness
Forgetfulness was reported, either indirectly or directly, as the main barrier to medication
adherence in four studies because of unintentional reasons, cognitive dysfunction (eg, attention,
mood, memory), psychological comorbidities (eg, anxiety, depression), and cognitive
side-effects from AEDs.1-2,15-16 Mobile applications (m-apps) were suggested to offset some
challenges with forgetfulness via features such as medication reminders and alerts, visual and
graphic depictions to track medication adherence, and on-demand education about medications
and diseases. These features may, if used consistently, could reduce hospitalizations due to
nonadherence.2,16-18
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Family/Caregivers and Socioeconomic Status
In four studies, factors influencing medication adherence were statistically significant as
follows: family size (p<0.05),1 fewer siblings (less rivalry for parents' attention) (p=0.03),3
mother's age (p<0.05),1 teen-caregiver conflicts, 2-3, 15 and unstable parents' marriage, (p<0.05).1
Family support was significantly correlated with medication adherence in four studies.1-3, 15 In
two studies, socioeconomic status (SES), such as financial constraints, healthcare access, and
problems with transportation, predicted low medication adherence.1, 15 One group of researchers
asserted that among AYA, 70% would benefit from reminders, which would lessen the burden of
reminding on caregivers, which led to exacerbated family discord or destabilization.2
Knowledge/Attitude about Disease
Greater knowledge about epilepsy and medicines or treatment plans were reported in four
studies as essential factors for AYA and caregiver medication adherence.2-3, 16-17 Similarly,
beliefs/attitudes and epilepsy knowledge were considered main factors influencing adherence in
five studies.1-3, 15-16 Some AYA reported concealing the disease to avoid feeling stigmatized or
embarrassed around peers when taking medications, and others felt that epilepsy somehow
signified "evilness," which may have negatively impacted adherence.1, 15 AYA and caregivers
who reported their medications as efficacious, however, demonstrated improved adherence.1-3, 15
Therapy-Related Factors
Number of Medications
Results were mixed in three studies regarding the number of prescribed medications and
their impact on AYA adherence.1-3, 15 In one study, researchers found that AYA with many
AEDs were more adherent, suggesting that more complex epilepsy demanded greater caregiver
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attentiveness in administering medications (p=0.042) as AYA self-reported that adherence was
not predicted by number of medications.3 One group found that in AYA who were prescribed
one AED, adherence declined by 2% per month, and on average, AYA missed one in four
doses.15 In contrast, other researchers found that AYA treated with one medication were more
adherent than AYA treated with greater than one (p<0.05).1
Side Effects of Medications
A factor that commonly impacts adherence in AYA is apprehension about perceived or
actual side effects.9 Results from four studies indicated that AYA might skip medication doses
due to fear of side effects (eg, gastrointestinal difficulties, drowsiness) and/or use m-apps to track
side effects.1,15,17-18
Medication Adherence Measurements
Subjective Measures
Morisky Medication Adherence Scale (MMAS)
The MMAS was used to measure mediation adherence among AYA in one study.1 It
consists of four items with scores ranging from 0 to 4. A total score of one or more was
considered poor adherence. No significant findings were reported in nonadherent participants'
scores (p=0.18).1 The tool's psychometric properties were not reported.
Beliefs about Medicines Questionnaire (BMQ)
In the study with the largest sample, the Beliefs about Medicines Questionnaire (BMQ)
was administered to 94 AYA.1 The BMQ consists of two sections: beliefs about medications in
general (BMQ-General) and beliefs about a specific medicine (BMQ-Specific).1 In a subscale of
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the BMQ-Specific, participants indicated perceptions about the necessity for specific prescribed
medication, with positive scores indicating stronger beliefs for necessity and negative scores
indicating the opposite. Results in this subscale indicated that 78 AYA had overall positive
scores, and 16 had negative scores.1
Pediatric Epilepsy Medication Self-Management Questionnaire (PEMSQ)
The PEMSQ for caregivers of AYA was administered in two studies.3,15 The
questionnaire consists of 27 items and four subscales: Epilepsy Treatment Knowledge and
Expectations (ETKE, (8 items), Adherence to Medications and Clinic Visits (AMCA, 8 items),
Barriers to Medication Adherence (BMB, 8 items), and Beliefs about Medication Efficacy
(BME, 3 items). The PEMSQ is considered to have good reliability, with a Cronbach alpha
between 0.68 to 0.85.15 Mean subscales and total self-management scores are calculated with
higher scores indicative of greater adherence.3
Pediatric Epilepsy Side Effect Questionnaire (PESQ)
One group of researchers administered the PESQ, consisting of 19 items. The PESQ is
based on a 6-point scale, with higher numbers indicating higher severity of side effects
(neurological, gastrointestinal). The tool is reported to have excellent reliability and validity,
with a Cronbach alpha of 0.92.15
Adolescent Epilepsy Medication Self-Management Questionnaire (AEMSQ)
The AEMSQ was developed to match the PEMSQ 3 and consists of 27 items and four
subscales: ETKE (8 items), AMCA (8 items), BMB (8 items), and BME (3 items). The following
are the Cronbach alpha coefficients for the subscales: ETKE; 0.79, AMCA; 0.71, BMB and
BME 0.58 and 0.54, respectively.3 Mean subscales and total self-management scores are
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calculated with higher scores indicative of greater adherence. In the final analyses, only the
ETKE and AMCA subscales were included in this study.3
Objective Measures
Electronic Pill Monitoring System
An electronic pill monitoring system, Medication Event Monitoring System (MEMS ™)
or SimpleMed, was used in two studies.2,15 This system tracks the date and time when the
medicine cap or pill compartment is opened. The data is sent wirelessly via a secured network.2
In one of the studies, both AYA and their caregivers used MEMS ™. They jointly completed the
PESQ during four time periods (every 3-4 months for one year). Findings indicated that
medication adherence increased during the study (p=0.002) and after follow-up (p=0.03).15
Text Messaging
One study's focus was whether an application-based intervention involving text
messaging would be acceptable and feasible for AYA and caregivers.2 Before the study, a
medical chart review was conducted, and caregivers completed a background questionnaire. All
participants were given the MEMS ™ or SimpleMed and randomized to either an intervention
group (Groups 1-4) or a control group (Group 5). Group 1 consisted of AYA receiving text
messages only. Group 2 consisted of text messaging involving AYA and caregivers as a singlefamily communication session (to reduce conflict and nagging). Group 3 consisted of
application-based reminders for AYA only. Group 4 consisted of application-based reminders for
AYA and caregiver plus single-family communication sessions. Group 5 (control group of AYA
only) was given the Epilepsy Tool-Kit Application. Findings indicated that Group 1 had higher
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adherence at the beginning of the intervention than Group 5 (p<0.005).2 Adherence in Groups 2
and 4 eventually decreased over time.2
Mobile Application (m-app)
One group of researchers used an m-app (EpApp, a mobile application with input from
stakeholders) to measure knowledge and medication adherence in AYA and their caregivers.16
After exposure to the EpApp, AYA participants demonstrated a significant increase in
motivation to learn more about their epilepsy (p<0.005) and needed fewer reminders to take
antiepileptic medication (p=0.045).16 Use of an m-app may also, depending on its features, may
act as a liaison between caregivers and healthcare providers.16
Studies with a Combination of Subjective and Objective Measures
In three studies, a combination of subjective and objective measures was employed to
assess medication adherence among AYA, including patient-reported outcomes, an electronic
pill monitoring system, and an m-app.2, 15-16 Findings were mixed, indicating either adherence or
nonadherence to the medication regime, which attests to the complexity of factors that influence
adherence.
Discussion
Medication adherence is an essential component of disease management, safety, and
quality of life. This integrated review revealed factors influencing medication adherence and
common measurements used to assess adherence in AYA. Although factors that influenced AYA
were similar to those of the general population with chronic diseases,9 findings suggested that
more in-depth classifying strategies are needed to adequately explore complex barriers and
facilitators affecting this population (eg, stratified age span/developmental stage, caregiver
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type/age, stigma-related perceptions, side effects, family cohesion, etc.). Differentiating these
factors is foundational for building enhanced medication adherence protocols among populations
likely to experience adherence differently. Both subjective and objective measures that have
been validated and shown to be reliable would help substantiate findings.
Patients and families are unique. Although some headway has been made in
understanding nonadherence among AYA, it may never be completely understood due to the
complexity of influencing factors and the differences in individuals' beliefs and circumstances.
AYA and their families may experience stigma surrounding the diagnosis, which can impede
trusting their communities and healthcare providers. Researchers must recognize the importance
of building rapport with patients, families, communities, and other healthcare workers involved
in patients' lives. Potential study participants need to know they are the main stakeholders and
not "guinea pigs" for research. A positive change in perception may help dispel distrust,
empowering disclosure about disease-related fears and struggles, likely enhancing understanding
barriers.
In addition to the benefits of increased researcher-stakeholder trust, analysis of adherence
complexities may be advanced by several pertinent, investigative enhancements. More depth and
complexity in the classification of adherence barriers and facilitators should be developed (eg,
developmental stage). Consistency in the terminology used to describe "adherence" and factors
affecting it should be an important consideration. Reliable, valid, subjective, and objective
measures are needed to substantiate findings. In addition, a concerted effort should be spent to
recruit underrepresented populations, and sample sizes and length of studies should be increased
to strengthen results and enable the generalization of findings. The research community can thus
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systematically approach this complex area of study to design effective, developmentally
appropriate interventions.
Limitations
This review consisted of studies with relatively small sample sizes and lacked diversity as
most participants were Caucasian except for a study conducted in Saudi Arabia with participants
from that region. Lack of scientific appraisal for m-apps geared for AYA was another
limitation,18 as was the length of studies. Although one study was conducted over a year,15 all
other adherence trials were short. Any one of these factors limits the generalization of findings in
the AYA population.
Conclusion
There are no gold standards for measuring medication adherence, which is
understandable, considering its complexity. Although subjective measures like self-reports and
surveys present a convenient way for researchers to assess adherence information, a major
drawback may be that results are underreported or overreported. These subjective measures need
to be further tested for their psychometric properties specific to AYAs. On the other hand,
objective measures are typically expensive, medication ingested is not observable, and
technological issues may arise that prove burdensome for AYA and/or their caregivers. More
research is necessary to explore evidence-based approaches for understanding medication
adherence among AYA, including more robust measures to offset the challenges inherent in this
complex population with adherence barriers.
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CHAPTER THREE: THE EFFECT OF THE MEDILEPSY MOBILE APP ON
MEDICATION ADHERENCE AND TRANSITION READINESS IN ADOLESCENTS
AND YOUNG ADULTS WITH EPILEPSY: A QUASI-EXPERIMENTAL STUDY
Abstract
The primary aim of this four-week study was to test the effect of Medilepsy, a novel
mobile app (m-app), on medication adherence in adolescents and young adults with epilepsy
(AYA), ages 16-24, with and without caregiver support. Secondary aims were to examine
Medilepsy's effect on transition readiness skills and to evaluate its usability.
A one-group, quasi-experimental pre-post study design was used. Before the study,
participants self-reported the past seven days of their medication adherence (number of
medication doses taken divided by the number of doses prescribed x 100%) documented as the
pre-medication adherence rate (AR) score. Participants completed the Transition Readiness
Assessment Questionnaire (TRAQ), a validated five-point Likert scale to measure transition
readiness pre-and post-study. The mHealth App Usability Questionnaire (MAUQ), a validated 7point Likert scale, was completed by participants post-study to rate Medilepsy's usability in three
domains: Ease of Use, Interface and Satisfaction, and Usefulness. A repeated measures test, the
Friedman test, was used to analyze changes in pre-AR scores and medication adherence at five
different time points: Time 1=pre-AR, Time 2=Week One, Time 3=Week Two, Time 4=Week
Three, Time 5=Week 4. A Wilcoxon test was used to analyze mean pre-post TRAQ scores.
Participants included 31 AYAs from 16 states (mean age 20.9 years; females, 73.3%,
Caucasian, 93.3%, and College-educated, 76.6%). The sample consisted of mostly younger
adults (93.3%) with no caregiver support. There was no significant improvement in medication
adherence mean scores at the five different time points (99.3% to 96.3%), χ2(4) = 8.40, p =
0.078. Pre- and post-TRAQ mean scores were statistically significant, p<0.001, and showed the
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greatest improvement in the following two domains: Appointment Keeping (3.46 to 4.00;
13.75% increase) and Managing Medications (4.03 to. 4.48; 11.25% increase). MAUQ's mean
scores were 5.94, with 7 as the highest total possible mean score. In the categories of Ease of Use
and Interface and Satisfaction, means scores were 6.09 of 7 for both. Participants graded
Medilepsy at 82.3% out of the maximum score of 100%.
Despite no statistically significant improvement in medication adherence, participants
gave positive feedback about using Medilepsy, particularly the text-messaging feature. This
study revealed higher mean scores for medication adherence than results reported in previous
research studies. The sample size was fewer than expected, yet there was enough power to detect
statistical change. The consent template language resulted in 11 eligible participants not
enrolling because of concerns about the security of their personal information.
This study contributes to the science of chronic disease self-management because it
illustrates the ability of Medilepsy to reach and engage AYA and caregivers. Medilepsy is a
reliable resource for educating AYA and caregivers, healthcare providers, and the epilepsy
community about medication adherence and transition readiness. Future studies should include
researchers' collaboration with their respective IRBs in adapting the consent language, expanding
the Medilepsy platform, consisting of different research designs, longer study durations, followups, younger participants, and increased underrepresented groups.
Keywords: adolescents, epilepsy, medication adherence, mobile app, transition readiness,
young adults.
Introduction
In the United States, 470,000 children and adolescents are diagnosed with epilepsy, with
over 150,000 newly diagnosed cases each year.1 Epilepsy is a common and chronic neurological
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disease often associated with unprovoked seizures greater than 24 hours apart or one unprovoked
seizure with a probability of reoccurrence within ten years.2,3 Epilepsy is sometimes described as
a "spectrum of disorders" because persons with epilepsy can have varying degrees of
comorbidities and symptoms.4 The primary treatment for epilepsy is antiepileptic drugs (AEDs),
which do not cure the disease but help control seizures.2,4
Medication adherence is the congruence or percentage level to which patients' medication
behavior complies with their providers' treatment recommendations.5 Nonadherence to AEDs is
30% or greater in adolescents and young adults with epilepsy (AYA) and can result in
exacerbation of seizures, high healthcare costs (> $100 billion), and mortality.5,6 Researchers
have reported that nonadherence in AYAs is linked to lack of transition readiness skills,7 which
refer to AYA's gradual independence in the management of the disease, adherence to prescribed
medications, self-advocacy skills, and the successful transfer of care from a pediatric model to an
adult healthcare model.7-10 Transitional readiness skills encompass patient/family/healthcare
provider collaborations to plan, implement, and execute an individualized plan for successfully
managing the disease, which is typically a complex and challenging process.7-10 Transition
barriers may include patients' and caregivers' fears of the unknown, frustration, anxiety,
perceived rejection from providers, and an uncoordinated transitional plan.7-10 Facilitators of
transition include patient-caregiver-provider trust, early readiness screening and implementation
of developmentally appropriate strategies, and open communication about the patient's
trajectory, treatment options, and medical plan.7-9,11 Medication nonadherence and lack of
transition readiness skills are thus global challenges for AYA and their caregivers.
No studies found in the literature used an intervention to measure transition readiness in
AYA with and without caregiver support. In 2014, the Transition Readiness Assessment
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Questionnaire (TRAQ)12 was developed to measure transition readiness in different chronic
disease populations of youth ages 16-26 with special healthcare needs (including AYAs).14 The
20-item TRAQ 5.0 (Appendix A) was revised in 2021 by eliminating the subscale of Managing
Daily Activities and adding 15 more items and a new subscale titled Future Planning.13 In 2020,
the EpiTRAQ was adapted from TRAQ 5.0 to include items relevant to people with epilepsy and
tested with patients 16-26 years of age.14 One group of researchers used TRAQ findings to
validate a social-ecological model (SMART) of transition readiness in AYA with epilepsy aged
13-25 (mean age 17.3 years).8 An important finding was that younger adults demonstrated
greater transition readiness compared to adolescents, p<0.001.8
Medication adherence among AYA has been examined using an m-app.15 In one study,
AYA exposed to an m-app for four weeks demonstrated a significant increase in knowledge
about epilepsy (p<0.005)15 and needed fewer reminders to take their AEDs (p=.045).15 Recent
study findings indicate that mobile apps (m-apps) can help support cognitive function and selfmanagement strategies for adolescents with chronic conditions and AYAs.15-18 In the US, over
74% of adolescents and young adults own smartphones, and half use these devices for
educational reasons.19 More than 90% of youth with chronic diseases and their caregivers
(including AYA) reported they would use m-apps for disease self-management.15-18 Benefits
include on-demand education and strategies, tracking and monitoring symptoms, goal setting,
communication with providers, and diaries.15-18 Despite the promise of m-apps, a large gap
remains in the US regarding studies that focus on testing their efficacy on medication adherence
and transition readiness in AYAs, with and without caregiver support.17,19,20 Moreover, the
design and content of several commercial m-apps on the market lack scientific appraisal and are
primarily adult-oriented rather than youth-oriented.16,20
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Researchers from the American Academy of Pediatrics, the American Epilepsy Society,
the Child Neurology Foundation, and the American Academy of Neurology have called for
future studies investigating innovative technology.8,21 In response to this call, Medilepsy, an
iPhone m-app, was created to test its effect on medication adherence and transition readiness in
AYA between 16-24 years old, with and without caregiver support. This selected age group was
based on one of the only validated and reliable measures for examining transition readiness, the
TRAQ.12
Specific Aims/Hypotheses
1. To examine the effect of Medilepsy on medication adherence in AYAs ages 16-24 years
with and without support before and after the intervention.
a. H.1.1 AYAs will have a significant improvement between their pre-AR and AR
mean scores at five different time points of the intervention (Time 1=pre-AR,
Time 2=Week One, Time 3=Week Two, Time 4=Week Three, Time 5=Week 4).
2. To examine the effect of Medilepsy on transition readiness before and after the
intervention.
a. H.2.1 AYA will have a significant improvement in their transition readiness mean
scores pre-post intervention.
3. To evaluate the usability of Medilepsy by AYAs with and without caregiver support poststudy.
Framework Used to Guide the Study
The Revised Self-Management and Family Management Framework (RSFM) provided an
appropriate and comprehensive framework to guide this study.22 The RSFM focuses on the
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science of self-management that pertains to understanding the complexities of chronic diseases
such as epilepsy in the context of facilitators and barriers, processes, proximal outcomes, and
distal outcomes.22 The Medilepsy intervention was integrated into this framework (Table 3) to
understand better its effect on medication adherence and transition readiness skills in AYA and
their caregivers.

Table 3. RSFM Model and Integration of the Medilepsy Intervention
Facilitators/ Barriers 1

Processes 2

Medilepsy Intervention

Proximal Outcomes 3

Focusing on Illness

Medication Adherence:

Specific Aim 1:

Future Directions:
Distal Outcomes

Personal/ Lifestyle

Needs
Beliefs, perceptions, and
knowledge.
Health Status

Medication reminders,

Medication Adherence

Health Status

safety alerts, medication

Adherence Rate

Control

Scores

education, and resources
to promote health and

health care needs

ownership of medication

Specific Aim 2:

Health Promotion

needs.

Transition Readiness

Individual Outcomes

TRAQ Tool

Quality of Life

about basic health

Specific Aim 3:

Family Outcomes

Health Care

insurance information,

Usability of Medilepsy

Psychological

wellness, and lifestyle

Function: Role of
Caregiver

Comorbidities,

Activities

Transition Readiness:

Cognitive Function

Activating Resources

Resources are provided

Symptoms/side-effects
Resources

Mortality

Learning
Taking ownership of

Spiritual

questions to ask

Community

Social

providers and support

Financial

Community

Morbidity

Quality of Life

forums, which may
encourage AYAs and

Living with Condition

caregivers to work
together and build trust,

Processing emotions

leading to healthier

Making Adjustments

adjustments and epilepsy

Integration and.

integration in daily

Making Meaning

activities life.

Contributing scholars of the RSMF Model are Schulman-Green et al., 2012, 2014; Ryan & Sawin, 2009).22

Facilitators and Barriers are primarily classified as Personal/Lifestyle and Health Status
factors that can influence self-management.22 Personal/Lifestyle involves a person's knowledge,
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beliefs, emotions, and life patterns.22 Patients and families have individualized sociocultural
beliefs and perceptions that can successfully promote or hinder efforts to manage chronic
disease.22,23 For example, some AYAs and their caregivers conceal epilepsy and isolate
themselves due to fear of discrimination and stigmatization, which can impede maximizing
recommended treatment benefits while transitioning into adulthood.23AYAs and caregivers who
possess knowledge about the disease, have a support system in place, and understand goals of
care and treatment options may be more engaged in adherence and learning transition readiness
skills.7-9,117Health Status includes comorbidities, cognitive functioning, symptoms, and side
effects relative to AYA and caregivers.22 Anyone's condition or combination of them can affect
AYAs' or caregivers' ability to manage seizures, symptoms, side effects of medications, and
psychological distress, all of which impact management of epilepsy.5,7,9,11 Thus, knowledge,
health status, and access to resources are vital for managing a complex, chronic disease.22,23
Processes target skills and strategies to manage chronic disease.22 These processes
incorporate three main factors: 1) Focusing on Illness Needs includes learning, taking ownership
of healthcare needs, and engaging in health-promoting activities,22 2) Activating Resources
involves AYA and caregiver coordination of healthcare services, communicating with providers,
and managing spiritual, psychological, social, and community needs and challenges,22 and 3)
Living with the Condition involves coping, processing emotions, making adjustments 22 and the
integration of the condition of epilepsy in activities of daily living. 23 Epilepsy is a disease that
affects the entire family unit.11,23 Managing epilepsy should be targeted as a family unit rather
than a separate entity involving only the AYA.11,24 Processes that involve epilepsy management
include: learning about the disease, taking ownership of healthcare needs, acquiring strategies
and skills to demonstrate optimal mastery of medication adherence, and transition readiness.11,23
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Caregivers having a support system and professional guidance as resources may reduce some of
the challenges and preparation necessary for the transfer of healthcare duties to AYAs.22,24
Adolescents provided with medication reminders, education, and strategies to manage
epilepsy have demonstrated enhanced medication adherence and transition readiness.19,20 The
Medilepsy intervention was developed to improve medication adherence and transition readiness
in AYAs via a virtual environment with features that provided education about epilepsy, the
importance of adherence and transition, medication alerts/text messages/emails, visual graph
trackers to monitor progression, warning alerts to encourage AYA to take medication as
prescribed, positive messages, and a voluntary Rewards Program to motivate engagement. The
information gained from this study was used to advance the science of self-management by
extending the RSFM framework.
The RSFM framework defines Proximal Outcomes as those affected by modifying
cognitions and adherence behaviors in persons diagnosed with a chronic disease.22 Scholars call
for action refers to a better understanding of how interventions work.22 Medilepsy provides
reliable educational resources and tips about medications, disease, basic health insurance
coverage, questions to ask providers (personal and difficult topics), strategies to improve diet and
lifestyle, and links to support forums to connect AYAs and caregivers to their epilepsy
community. These are highly useful life skills and transition readiness tools.16,17,20 In addition,
they may help AYA and their caregivers with adjustments needed to integrate aspects of the
disease into daily life activities.17-19 Distal Outcomes include Health Status (control, mortality,
morbidity)22 and Individual and Family Outcomes (quality of life and function),22 which extend
beyond this study.
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Methods
Research Approach
A one-group quasi-experimental pre-post study design was used to examine medication
adherence and transition readiness in AYAs. A baseline medication AR score was self-reported
by participants based on the past seven days (number of medication doses taken divided by the
number of doses prescribed x 100%) 25 and documented as the pre-AR score. During the 4-week
study, medication adherence entries were tracked by the Medilepsy admin panel and were
calculated during five different time points (Time 1=pre-AR, Time 2=Week One, Time 3=Week
Two, Time 4=Week Three, Time 5=Week 4). Transition readiness was calculated using TRAQ
pre- and post-mean scores.12 Participants were asked to complete the electronic mHealth App
Usability Questionnaire (MAUQ) post-study (Appendix B).26 The enrolled caregivers opted out
of taking the surveys.
Ethics
The Institutional Review Board at the University of Central Florida (UCF) in Orlando,
Florida granted an expedited review approval for this study (IRB ID: STUDY00002635).
Participants' data were deidentified.
Recruitment and Consent
Participants were recruited from neurologist and epileptologist providers' offices, Florida
universities/colleges, professional nursing organizations, and social media platforms
(LinkedIn™, Facebook™, and Instagram™). Caregiver participants were enrolled to provide
oversight of AED medications for adolescents ages 16-17. Recruitment took place from February
2021-August 2021. Materials consisted of a flyer (Appendix C) emailed and mailed to healthcare
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providers, organizations, and local businesses. The study was advertised nationally in newsletters
and social platforms by several epilepsy foundations, nursing organizations, Florida
universities/colleges, and social media epilepsy bloggers. The PI participated in live interviews
with epilepsy advocators and epilepsy bloggers on YouTube and interacted with AYA on social
media platforms. Snowball and convenience sampling were implemented. Adolescents received
a $50.00 VISA card for completing the four-week study. Caregivers were not compensated.
Inclusion Criteria
Participants were included if they were between the ages of 16-24, had a formal medical
diagnosis of epilepsy, lived in an outpatient setting, had access to an iOS mobile device with a
reliable internet connection, and gave verbal informed consent. Participants < 18 years old had to
have a caregiver who also gave verbal informed consent.
Exclusion Criteria
Participants were excluded if they did not speak, read, or understand English, if they had
drug-resistant epilepsy, answered "yes" to having a documented severe intellectual disability, or
were unable to operate a keyboard or press phone buttons on a mobile device. Participants were
also excluded if they missed the Medilepsy training sessions and did not interact with Medilepsy
for a minimum of three times a week during each week of the 4-week study.
Setting
The study was conducted in the United States with AYA with and without caregivers in
non-hospital settings.
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Research Variables
In this study, the independent variable is the Medilepsy m-app. The dependent variables
are medication adherence and transition readiness skills.
Data Collection
The following demographic and clinical data were collected from enrolled AYA
participants: age, gender, race, grade level, zip code, epilepsy syndrome, seizure type(s),
frequency of seizures (weekly), number of medications, medication name(s)/dose/frequency.
Medication adherence scores were tracked on the Medilepsy admin panel during the entire study.
The PI used a check-off list to document completion of the following: inclusion and exclusion
screening, verbal assent, informed consent, enrollment and training sessions, competency using
Medilepsy, study start and completion dates, pre-AR score, data collection times, and
checkpoints of weekly medication adherence entries during the 4-week study, pre-post TRAQ
and MAUQ post-surveys.
Development of Medilepsy M-app
The PI created Medilepsy and collaborated with an engineer, a research assistant, and a
contracted mobile app developer. Medilepsy was programmed in SWIFT, and an admin panel
was created. The PI and research team used password-protected access to retrieve, store and
manage the data. This study's admin panel consisted of each participant's medical profile,
medication notifications received/medication entries marked, caregiver notifications, medication
library, and other features. The admin panel was also designed to work with the backend,
Amazon Web Services (AWS),27, a web-based content management system with a secured cloud
application used by developers and researchers to create and manage m-apps.27
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Medilepsy was designed with features to help participants remember to take their
medications, learn reliable information about epilepsy, and access resources about disease
management and transition readiness skills. Educational content and other resources were
derived from a literature review. The PI also received approval from several organizations to use
resources to support medication adherence and transition readiness. Both text and videos were
offered with accessible hyperlinks embedded in the app's Chatbot (Tables 4 and 5).
Medilepsy has the following features: My Notes, Reminders, a voluntary Rewards
Program, Daily Adherence Diary, Visual Graph Tracker, Tutorial, Chatbot, a private
Instagram™ platform, and the Medilepsy website 28 (Figure 1). Adolescents and caregivers had
access to learn about epilepsy basics,29 side effects of medications,30 "share your story" blogs,
contact information regarding participants' local epilepsy foundation, 31 Seizure First Aid and
Epilepsy Toolkit,32 a novel crossword puzzle, and music streaming.28
Medilepsy's content to support medication adherence (Table 4) includes hyperlinks to
educational resources such as types of epilepsy, medications and side effects, memory boosting
techniques, adherence tracking features, medical history, a personal journal, calendar, tutorials
about making the most of Medilepsy's adherence features, and contact information of providers
and pharmacies. Participants had access to the Instagram platform and the Medilepsy website to
interact with other participants and learn how to manage medications and side effects.
Medilepsy's content to support transition readiness skills (Table 5) includes hyperlinks to
educational resources and text for managing medication, appointment keeping, tracking health
issues, talking with providers, and managing daily activities. Specifically, AYA had access to
text and videos about teens transitioning,33 "questions to ask your doctor," 34 "talking to your
doctor," 35 "taking charge of your medical care," 36 health insurance basics,37 a 24/7 helpline,38
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managings epilepsy in the context of daily living and tips,39 and wellness and support tools.40 All
resources were automatically updated by the resource website manager.

Figure 2. Medilepsy's Features

Table 4. Medilepsy's Content to Support Medication Adherence
Features

Resource(s)

Targeted Goals for Participants

My Profile

Built-in
Medilepsy

Adolescents with epilepsy (AYA) can document knowledge about
disease medical history, medication schedule, and providers/pharmacy
contact information which are essential steps towards medication
adherence and transition readiness skills.

Reminders

Built-in
Medilepsy

AYAs can learn about their medications, side effects, and type of
epilepsy to better understand their disease. AYAs receive reminders to
boost memory and enhance adherence, which may promote
independence and disease self-management skills.
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Features

Resource(s)

Targeted Goals for Participants

My Notes

Built-in
Medilepsy

AYAs can journal personal information about their feelings,
experiences, and concerns to reflect upon them or address them with
caregivers, providers, or others of their choice.

Rewards
Program

Built-in
Medilepsy

May motivate AYAs to adhere to medications and manage epilepsy by
setting personal goals, promoting transition readiness skills.

Daily
Adherence

Built-in
Medilepsy

AYAs can visually track their daily adherence via a calendar and graph.
AYAs may be able to identify challenges or symptoms that interfere
with activities of daily living to make healthy choices and adjustments.

Visual
Graph
Tracker

Built-in
Medilepsy

AYAs can visually track their daily adherence via a calendar and graph.
AYAs may identify lifestyle challenges or symptoms that interfere with
optimal adherence, health, and quality of life.

Chatbot

Medilepsy.com
Epilepsy.com
Nemours
Children's Health
System,
TeensHealth.
FDA

AYAs learn in a virtual environment and access reliable hyperlinks to
educational resources presented in text, audio, and videos. The
following information is provided: Medications and side effects, 24/7
hotline (EF. for referrals basics about epilepsy health insurance, seizure
first aid, current epilepsy treatments, and health transition strategies.

Tutorial

Built-in
Medilepsy

AYAs have access to tutorials that can help reinforce how to access
features of Medilepsy to stay on track with taking medication learning
strategies by asking for help or addressing concerns, which may
promote independence and promptly resolve any technical challenges
with the app.

Table 5. Medilepsy's Content to Support Transition Readiness Skills
Features

Resource(s)

TRAQ
Targeted Goals of Participants
Domains
My Profile
Built-in Medilepsy M 1. Managing Medilepsy provides reliable hyperlinks to
Reminders
Medilepsy.com
Medications educational resources presented in text, audio, and
Daily Adherence
Epilepsy.com
video formats: medications and side effects,
FDA
Visual Graph
seizure first aid, current epilepsy treatments.
EF
Tracker
Local EF offices, employment tips, and reporting
CDC
Chatbot
discrimination. AYAs can also work in
Rewards Program
partnership with a person of choice to set goals
Tutorial
and be rewarded, which may boost self-efficacy
and transition readiness skills.
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Features

Resource(s)

TRAQ
Targeted Goals of Participants
Domains
Chatbot
Built-in Medilepsy
2.
AYAs can learn transition strategies for taking
My Notes
Medilepsy.com
Appointment charge of their health, facts about health insurance
Daily Adherence
EF
Keeping coverage, preparing for appointments to discuss
Nemours
Children's
Visual Graph
confidential matters with providers, and the latest
Health
Tracker
information about epilepsy treatments. AYAs can
learn to make appointments, check on labs, and
report unusual symptoms to promote self-efficacy
and transition readiness skills.
Chatbot
Built-in Medilepsy 3. Tracking AYAs can track their health issues by journaling
My Notes
Medilepsy.com
Health Issues questions, feelings, and experiences to share or
Daily Adherence
EF
ask providers. AYAs can track their adherence
Nemours Children's
Visual Graph
progress using the features on Medilepsy
Health
Tracker
(calendar/graph). A 24/7 hotline is offered to get
Rewards Program
referrals for emotional support, local support
groups, local EF chapter, seizure first aid, and
current epilepsy treatments. Resources can help
AYA adjust, set goals, and integrate practices that
help meet their individualized goals.
Chatbot
Built-in Medilepsy
4. Talking AYAs can jot notes and questions on Medilepsy
My Notes
Medilepsy.com with Providers to help them remember important things to
address with their provider(s). AYAs can access
EF
links to learn strategies addressing confidential
Nemours Children's
care matters and health services. Strategies and
Health
resources may help participants to reduce stress
levels and build trust with providers and others.
Chatbot
Built-in Medilepsy 5. Managing AYAs have access to the EF Wellness Institute,
My Notes
EF
Daily
which provides education about diet and nutrition,
Instagram Page Nemours Children's Activities living independently, and other relevant resources
Health
Medilepsy
such as a downloadable wellness toolkit. AYAs
https://www.instagra
Website
can also interact with other participants on the
m.com
Instagram page and Medilepsy website to share
stories, blogs and learn about how others manage
their daily activities.
TRAQ Survey
Built-in Medilepsy
AYAs can review their answers to their prePre-TRAQ Survey
TRAQ scores. However, AYAs were not able to
edit or modify their responses to the survey.
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Procedures
Pre-Intervention Training Sessions
After verbal consent was obtained, participants and the PI scheduled two private, onehour virtual training sessions. Participants received a link to download Medilepsy on their iOS
device from TestFlight (Figure 3). Once Medilepsy was downloaded, participants were
instructed about the features of the m-app. Next, participants viewed a short built-in tutorial
about features on the app that could help troubleshoot problems (eg, how to reset a password).
During this pre-intervention session, the PI interviewed participants by phone and zoom
using the My Profile section of Medilepsy that mimics a medical history form. The PI asked
each participant to fill out this section as the interview took place. The PI asked participants
about the following: demographics, medical and medication history, healthcare providers, and
pharmacy contact information. This data could be updated by participants during the study and
subsequently by the PI.

Figure 3. Medilepsy Link from TestFlight
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Next, the PI and participants set up medication schedules in the Reminders section of
Medilepsy. AYAs were allowed to provide pictures of their antiepileptic drugs AEDs to include
on the medication reminder screen. Many participants wanted to add other medications like
antidepressants or birth control pills, so these were added to the Reminder section along with
their AEDs.
Finally, the PI and participants reviewed all features of Medilepsy, which included
inputting their medications and accessing Chatbot, Visual Graph Tracker, Daily Adherence
Diary, Rewards Program, the Medilepsy website, and the Instagram platform. A Down-time
Medicine Log was also provided and reviewed with participants for documentation if Medilepsy
malfunctioned or participants experienced any technical issues or interruptions to their internet
service (Appendix D). Technical issues were handled by the PI and tech support and were
typically resolved within 24 hours.
The voluntary Rewards Program was introduced and started on Week One of the study,
ending on Week Four. The goal of the rewards program was to incentivize AYAs to take their
medications. Participants could earn one point per medication taken on time, and it was tracked
on the Medilepsy compliance scoreboard. Rewards are typically good motivators for adolescents
and may promote healthy behaviors and learning new habits.41 M-apps is an interactive platform
that can provide adolescents to learn about their disease, address goals, and promote selfmanagement skills.17,19 Adolescents could create personal weekly goals and rewards with the
option of working together with a caregiver or another person of choice.
Pre-Intervention Assessments
A baseline medication score was self-reported by participants based on the past seven
days (number of medication doses taken divided by the number of doses prescribed x 100%) 25
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and was documented as the pre-AR score by the PI on the training checklist. The PI also asked
participants to complete the TRAQ 20 (Appendix A), documented on the training checklist as the
pre-study TRAQ score.
Early, On-time, and Late Classification of Medication Reminders
Participants were encouraged to wait until their prescribed medication times to take
medications and were told that Medilepsy would remind them via push notification and text
messages 30 minutes before and at the correct time. A medication was considered "taken on
time" when participants took their medications at their prescribed time. A "too-early" medication
entry was considered an attempt to take medication > 2 hours earlier than prescribed. When this
happened, a safety message alert was generated, "It's a bit too early to take your medicine. Don't
worry; we'll remind you when it's time to take your medicine." A "late dose" was defined as a
medication taken 30-60 minutes after the prescribed time. A missed dose was defined as the
absence of "marked taken" on Medilepsy by the cut-off time of 11:57 PM Eastern Standard
Time. The cut-off time allowed the database system to reset for the following day.
Medilepsy Intervention
Participants were asked to interact with Medilepsy to access resources and mark their
daily medication with a minimum of three medication entries per week for the four-week study.
Participants received daily medication reminders, which consisted of push notifications, text
messages, and emails. Each day, for example, participants received a 30-minute "heads-up" text
message that medication time was approaching. Adolescents received a text message and push
notification (pop-up message) at the scheduled medication time. If the medication was marked
"taken," participants received a positive message, "Great job!" and earned one point on the
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scoreboard under Rewards (Figure 4). All participants received an email confirmation and a text
message that medication was marked or missed. If the medication was not marked "taken," the
participant received another medication reminder after 30 minutes, which continued at the next
30-minute interval. If the participant did not mark medication taken after an hour or missed
the11:57 PM cut-off, the enrolled caregiver received a text notification and an email indicating
the late and missed dose (Figure 3).

Figure 4. Medication Reminders, Positive Messages, and Reward Scoreboard

Medilepsy Intervention: Caregivers
For four weeks, enrolled caregiver participants used Medilepsy to access all features
except "mark medications taken" for their AYA. This feature was disabled. Caregivers were
notified via text and email for the following: medication marked taken, medications marked >2
hours earlier than the prescribed time, medications marked >1 hour late of the scheduled
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medication time, and a missed dose of any medication. Caregivers were invited to complete
TRAQ and MAUQ surveys, which were not required per the study protocol. The caregivers
opted out of completing the surveys, and no data analysis was conducted.
Outcome Measures
Medication Adherence Scores
Before starting the study, participants were asked how many medication doses were taken
of prescribed medication over the past seven days. The PI then calculated the medication pre-AR
(number of medication doses taken divided by the number of doses prescribed x 100%).25
Medication adherence scores were recorded and calculated using medication entries from Week
One through Week Four. A repeated measures test, the Friedman test, was used to analyze
changes in pre-AR scores and medication adherence at five different time points (Time 1=preAR, Time 2=Week One, Time 3=Week Two, Time 4=Week Three, Time 5=Week 4).
Transition Readiness Scores
The Transition Readiness Assessment Questionnaire (TRAQ) Version 5.0 12 was
administered to all participants pre-and post-study. The psychometric properties of the TRAQ
are reported as reliable and valid, with a Cronbach's alpha value of 0.92 for self-management and
0.82 for self-advocacy.12 TRAQ measures transition readiness skills in five domains: managing
medications, appointment keeping, tracking health issues, talking with providers, and managing
daily activities (Appendix A).12 TRAQ has been evaluated in youth aged 16-24 years old with
various complex health issues including Type 1 and Type 2 diabetes, cystic fibrosis, epilepsy,
sickle cell disease, cerebral palsy, autism, and other chronic conditions.8,12 TRAQ 5.0 consists of
20 questions and employs a 5-point Likert scale that can be completed by the patient, caregiver,
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or both.12 Results are based on the TRAQ mean scores of all participants, ranging from one to
five. Higher scores indicate greater transition readiness (1= I do not know how to do this, 2=I do
not know how, but I want to learn, 3=I am learning how to do this, 4=I have started doing this,
5=I always do this when I need to).12
Usability of Medilepsy
The mHealth App Usability Questionnaire (MAUQ) 26 was administered to all
participants post-study (Appendix B), and all 30 participants completed the anonymous
questionnaire. The psychometric properties of MAUQ are reported as valid and reliable.26 The
validity was performed using exploratory factor analysis, and the overall Cronbach's alpha value
is 0.91.26. The tool consists of 18 questions and employs a 7-point Likert scale.48 There are three
domains on the MAUQ: Ease of Use (questions 1-5), Interface and Satisfaction (6-12), and
Usefulness (13-18). Scores range from 1-strongly disagrees to 7-strongly agrees. Results of the
MAUQ are based on the usability mean scores. 48 The higher the mean, the higher the usability
score.26
Rewards Program Question(s)
Participants were invited to answer a yes or no question to determine if they participated
in the Rewards Program. Those who answered "yes" were asked an additional question, "On a
scale from one to five, with 1 (do not recommend the Rewards Program) and higher numbers up
to 5 (strongly recommend), how would you rate using the Rewards Program?" The higher the
mean, the higher the recommendation for using the Rewards Program.
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Statistical Analysis
A sample size of 41 participants was calculated based on a repeated measures analysis
with a moderate effect size (d = .40) with an α = .05 and 80% power. An attrition rate of 20%
was expected, so a total of 50 subjects were targeted for enrollment. The initial statistical
approach using a paired t-Test was revised to the Friedman's test (RM-ANOVA) to analyze any
changes in medication adherence during the 4-week study. The Wilcoxon test was used to
analyze the pre-post TRAQ mean scores.
All data were screened and cleaned in Excel before data analysis. A p-value of 0.05 was
set as the level of significance. The data were analyzed using IBM Statistical Package for the
Social Sciences (SPSS) Version 27.0 42 and statistical software R version 4.1.0.43 SPSS was used
to analyze descriptive statistics. Categorical variables were reported as frequencies and
percentages. Continuous level variables were reported as means and standard deviations. The
Wilcoxon test was used to analyze the pre-post TRAQ mean scores. Statistical software R
version 4.1.0. the Friedman's test analyzed any changes in the pre-AR scores and medication
adherence at five different periods Time 1=pre-AR, Time 2=Week One, Time 3=Week Two,
Time 4=Week Three, Time 5=Week Four.
Results
AYA Participants
A total of 58 participants were screened, and 31 AYA met eligibility (mean age was 20.9
years; females, 73.3%, and Caucasian, 93.3%, College, 76.6%). (Table 6). One participant was
withdrawn from the study for hospitalization, resulting in 30 enrolled AYA participants.
Participants were represented from 16 states. Education level consisted of high school, college,
graduate school, and other (Table 3). Primary epilepsy type was generalized, 60%, and the
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number of prescribed AEDs consisted of one AED, 36.6%; two AEDS, 40%. The two most
prescribed AEDs were Keppra (43.3%) and Lamictal (30%). Seizure activity within the past six
months was 46.6% (Table 6).
AYA Participants <18 Years with a Caregiver
A total of two adolescents under the age of 18 were enrolled with a caregiver. The
analysis did not include caregivers because the study examined medication adherence and
transition readiness in AYA with epilepsy. The caregiver's main responsibility was to monitor
their adolescent taking medications during the study.

Table 6. AYA Characteristics (n=30)
Variable

(%)
Demographic Variables
Gender

Female
Male
Non-Binary

73.3
26.7
3.33
Age (Years)

16-17
18-20
21-24

6.66
40.00
56.66
Education Level

High School
College
Graduate
Other

10.00
53.33
23.33
13.33
Race

Caucasian
Black
Other

93.33
3.33
3.33
Medical Variables
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Variable

(%)
Number of Prescribed AEDs

1
2
3
4 or >

36.66
40.00
16.66
6.66
Epilepsy Syndrome

Generalized
Focal
Unknown
Seizure Activity within the Past Six Months

60.00
20.00
20.00
46.66

Aim 1: Use of Medilepsy and Effect on Medication Adherence
The Friedman's test measured medication adherence at five different time points. There
was no significant improvement in medication adherence mean scores (99.3% to 96.3%), χ2(4) =
8.40, p = 0.078. No statistical improvement was found in the pre-AR scores and medication
adherence at the five different periods (Time 1=pre-AR, Time 2=Week One, Time 3=Week Two,
Time 4=Week Three, Time 5=Week Four). Nevertheless, medication adherence of 96.3 % is a
high score. However, 43.3% of participants missed taking at least one medication dose during
the 4-week study (Figure 5).
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Figure 5. Weekly Missed Number of Medication Doses in 13/30 Participants

Aim 2: Use of Medilepsy and Effect on Transition Readiness Skills
The Wilcoxon test revealed a statistically significant improvement in pre-and postTRAQ mean scores, p<0.001. The greatest improvement was seen in the following two domains:
Appointment Keeping (3.46 to. 4.00; 13.75% increase) and Managing Medications (4.03 to.
4.48; 11.25% increase) (Figure 6).
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Figure 6. Percentage of Increase in TRAQ Scores Within the Five Domains Measured

Aim 3: Usability of Medilepsy and MAUQ Scores
The overall MAUQ mean score for Medilepsy's usability was 5.94 of 7 (Table 8).
Descriptive statistics were used to depict means, from highest to lowest. In the three domains of
usability:1) Ease of Use, 2) Interface and Satisfaction, and 3) Usefulness, the highest mean
scores were Ease of Use and Interface and Satisfaction which were tied at 6.09 of 7. (Figure 7).
Participants graded Medilepsy at 82.3% out of the maximum score of 100%.
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Table 7. MAUQ Questions
Usability Criteria
The app was easy to use.
It was easy for me to learn to use the app
The navigation was consistent when moving between screens
The interface of the app allowed me to use all the functions (such as entering
information, responding to reminders, viewing information) offered by the app
Whenever I made a mistake using the app, I could recover quickly
I like the interface of the app.
The information in the app was well organized, so I could easily find the
information I needed.
The app adequately acknowledged and provided information to let me know
the progress of my action.
I feel comfortable using this app in social settings.
The amount of time involved in using this the app has been fitting for me.
I would use this app again.
Overall, I am satisfied with this app.
The app would be useful for my health and well-being.
The app improved my access to healthcare services.
The app helped me manage my health effectively.
This app has all the functions and capabilities I expected it to have.
I could use the app even when the Internet connection was poor or not
available.
This mHealth app provides an acceptable way to receive healthcare services,
such as accessing educational materials, tracking my own activities, and
performing self-assessment

57

AYA (n=30)
Mean (SD)
5.97 (1.22)
6.57 (0.56)
6.20 (1.11)
6.27 (0.77)
5.47 (1.43)
5.70 (1.46)
6.30 (1.00)
6.30 (0.74)
6.27 (1.12)
6.03 (1.22)
5.83 (1.46)
6.17 (1.07)
6.17 (1.21)
5.00 (1.21)
6.03 (0.95)
5.67 (1.49)
5.23 (1.80)
5.77 (1.12)

Figure 7. The MAUQ % Ratings by Domains

Participant's Feedback on the Rewards Program
No participants enrolled in the Rewards Program. One participant reported, "I did not
enroll in the program, but I used it to track my points which was cool!"
Discussion
This study provided value to better understand the effect of an m-app as an intervention
for medication adherence and transition readiness in AYA with epilepsy. In this study, the use of
Medilepsy did not improve medication adherence. The non-significant result was expected
because the scores could only move in one direction. LeMarne et al. found that AYA using an mapp for four weeks had a statistically significant improvement in medication adherence
(p=.045).15 This study revealed higher mean scores for medication adherence (99.3 % to 96.3%)
than results reported in previous research studies using an intervention.25 Smith et al. reported
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pre-post medication adherence scores in AYA over one year using an intervention called the
Medication Event Monitoring System (MEMS) TrackCaps.25 Adolescent's medication adherence
scores significantly decreased by 2% each month (86.0 % to 74.5%, p<0.001).25 Medication nonadherence can occur for many reasons, including forgetfulness (intentional or unintentional),
memory impairments, and seizure activity associated with the disease.5,15,25
There was a significant improvement in AYAs pre-post TRAQ mean scores (3.74% to
4.31%), p<0.001, indicating higher perceived transition readiness. There were no studies to
compare these findings that the author is aware of that used an intervention to measure transition
readiness using the TRAQ. However, it could be the case that older college-educated AYAs
involved in epilepsy advocacy groups may have rendered different results compared to the
general population without these demographics.
A surprising finding was the low attrition rate of 3.3 %, compared to the attrition rate of
19% reported by LeMarne,15 (number of participants dropped out [n=10] divided by the total
number of participants who completed the study [N=43]). Only one of 31 participants in this
study was withdrawn in Week Four due to hospitalization. The PI developed a strong rapport
with participants throughout the study. Recruitment methods of enrolled participants included the
use of snowballing (16%) and convenience sampling from a health care provider's (3%), epilepsy
bloggers/advocators on social media (49%), and the Epilepsy Foundation social media forums
(32%). Recruitment methods used in this study are effective in research studies, including those
with young adolescents and adults with chronic diseases.44,45 Adolescent participants who
completed the study were compensated with a $50.00 VISA card.
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Clinical Implications
Participants reported positive feedback using Medilepsy, such as it helped them remember to
take their medications, especially the text messaging feature. Medilepsy shows great promise as
a reliable resource tool that can help AYAs and caregivers monitor, assess, and learn medication
adherence and transition readiness that can be shared with healthcare providers and caregivers.
Medilepsy also has clinical implications for younger newly diagnosed adolescents, caregivers,
and the community at large.
Limitations and Future Directions
Recruitment
The COVID pandemic hindered recruitment and meeting with providers because many
offices were closed, used telehealth, and restricted guests from entering the offices. The PI met
with prospective participants via phone and zoom rather than face to face as planned. Ninety
healthcare providers were invited to participate via email, mail, and telephone with only one
response. The researcher's continued collaboration with participants, community stakeholders,
organizations that support research, and health care providers are necessary to strategize ways to
continue research objectives.
Sample
The target sample size was 41 participants. This study recruited 31 AYAs which was
fewer than expected, yet there was enough power to detect statistical changes. Participants ages
16-17 years and two caregivers comprised 7% of the sample. This underrepresentation highlights
the need for increasing research studies with younger participants and caregivers. There were
two minority participants. These findings highlighted the need for a larger sample size, younger
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participants, and more minorities of AYA in research studies. Building trust and rapport with
community leaders and exploring the use of analytic data platforms may increase participation in
underrepresented groups.
Study Design
This study used a one-group quasi-experimental design and convenience sampling, which
limited generalizability to the AYA population. Future studies should consider randomized
methods and a mixed-methods design to capture participants' real-life experiences and quantify
medication adherence and transition readiness.
Duration of study
The intervention in this study lasted for 4 weeks, as in LeMarne's study. A longer time frame
may allow AYAs and caregivers the opportunity to use Medilepsy's other features that could
help with monitoring and learning strategies for medication adherence and transition readiness.
Longer duration with more than one group and increased sample size may impact the research
outcomes. For example, computer-generated randomization would be used to assign participants
to either Group 1: using Medilepsy without reminders or Group 2: using Medilepsy with
reminders for at least three months.
Consent Template
The standard wording in the consent form, "Participant's information both identifiable
and de-identified may be used to create products or deliver service that may be sold to make
money," resulted in eleven participants declining to participate in this study. Recommendations
include working with the IRB to choose language so that participants know that their information
will be used solely for the research study and not for commercialization. Further, PIs may want
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to read the consent as a potential participant to identify any wording that seems contradictory to
protecting the participant's personal information and have potential participants read the consent
to get feedback prior to future studies.
Technical Issues
Technical issues were reported but did not disrupt the study. Participants reported the
disappearance of medication reminders, error messages, and receiving alert messages at incorrect
times. The admin panel could not collect page counts of the topics visited by the participants via
the Chatbot, which limited evaluating participants' literature topics of interest. Recommendations
include contracting experienced developers working within research settings and longer piloting
of the m-app.
Conclusion
This study contributes to the science of chronic disease self-management because it
illustrates the ability of Medilepsy to reach and engage AYA and caregivers. Medilepsy is a
reliable resource that can help patients, families, healthcare providers, and the community better
support and educate AYAs and caregivers on medication adherence and transition readiness.
Medilepsy has the potential to be expanded to other chronic disease management platforms.
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CHAPTER FOUR: A NOVICE RESEARCHER'S RECRUITMENT CHALLENGES
AND LESSONS LEARNED: ENROLLMENT OF ADOLESCENTS AND YOUNG
ADULTS WITH EPILEPSY IN A MOBILE-APPLICATION INTERVENTION
Background
Epilepsy is a common and chronic neurological disease associated with unprovoked
seizures and diverse symptoms often associated with psychological and cognitive comorbidities.1
In the United States (US), 470,000 children and adolescents live with epilepsy, with150,000 new
cases diagnosed each year.1 This paper describes challenges and lessons learned from participant
recruitment efforts for an interventional mobile application (m-app) study conducted in the US in
adolescents and young adults with epilepsy (AYA) during the COVID-19 pandemic.
Clinical research is heavily influenced by the enrollment of the targeted number of
eligible participants for a study.2 More than 60% of research studies fail to recruit the eligible
number of participants to meet research objectives.2 Reported recruitment barriers in the
literature included the following: vulnerable populations with chronic diseases failing to meet
eligibility criteria,2 lack of researcher and participant rapport in relationships,3 challenges with
pre-screening and locating marginalized younger participants,4 lack of researcher collaboration
with healthcare providers and organizations to promote research,2 costs to conduct studies,4
unwillingness of patients to participate in studies due to fears of contracting COVID-19,5 and
delayed clinical drug trials due to the pandemic's burden on the healthcare system.5 Effective
recruitment methods included the following: convenience and snowball sampling, communityor school-based recruitment, social media platforms,3,4 rapport with healthcare providers and
organizations, mass mailings, advertising in newspapers, television, radio and internet venues,
and applying predictive analytics or contacting data-analytic organizations for help with
recruitment for potential participant demographic information.2,3
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Methods
A one-group, quasi-experimental pre-post study design was used. Before the study,
participants self-reported their medication adherence (number of medication doses taken over 7
days divided by the number of doses prescribed) which was documented as the pre-medication
adherence rate (AR) score. Participants completed the Transition Readiness Assessment
Questionnaire (TRAQ), a validated five-point Likert Scale to measure transition readiness preand post-study. The mHealth App Usability Questionnaire (MAUQ), a validated 7-point Likert
scale, measured usability, ease of use, and satisfaction with Medilepsy post-study. An admin
panel tracked participants' medication entries using a secured database. The recruitment methods
employed were convenience and snowball sampling, healthcare provider referral, social media
venues, collaborations with epilepsy organizations, epilepsy bloggers, and advocators.
Recruitment During the COVID-19 Pandemic
Recruiting participants diagnosed with a chronic disease for research studies is
demanding and time-consuming.2,3 In the wake of a pandemic, it is even more challenging.2,3,5
The study target sample was 41 participants, but only 31 participants were recruited during the
limited six-month timeframe. The recruitment methods involved distributing flyer
advertisements to local college campuses via email. Also, pediatric neurologists, epileptologists,
healthcare providers, community health centers, Nurses' agencies, and epilepsy organizations
across the US. were emailed, called, and mailed letters with the flyer.
Healthcare Providers, Special Needs Clinic, and National Epilepsy Foundations
Typically, an effective recruitment strategy, particularly for this population, is a referral
from AYAs' epilepsy-related healthcare providers, which correlates with a high level of
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participation.2,3,5 During the study period, the traditional patient-healthcare provider relationship
was altered by quarantining, social distancing, and other isolating protocols. Lack of
collaboration with healthcare providers greatly reduced this conventional method of promoting
the study. Only one out of 90 healthcare providers contacted referred a participant that was
enrolled. (Figure 8).

Figure 8. Recruitment Methods
However, it is not uncommon for systematically marginalized groups to use digital
platforms rather than face-to-face communication channels to offset the lack of in-person
interaction.4 The University of Central Florida Center for Autism and Related Disabilities
(CARD) promoted the study in their newsletter. However, no one reached out. The researcher
then contacted the Epilepsy Foundation of America (EFA) for help in advertising the study. The
Epilepsy Foundation agreed to leverage its online presence, particularly through social media
platforms and Instagram, which did promote a degree of interest in the study. Suddenly, people
from around the country inquired about it, and ultimately, 10 participants were enrolled. From
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there, the recruitment strategy shifted from traditional advertising methods to social media
promotion almost exclusively. Once the researcher began establishing relationships with the
online community, the researcher reached more people (Figure 8).
Social Media Platforms
The University of Central Florida and local Florida Colleges advertised the study through
email blasts and social media platforms to nursing, computer science, engineering students,
faculty, staff, and alumni. Several potential participants emailed the researcher to express
interest, but scheduling follow-up consultations to discuss participation proved difficult. Roughly
eight people did not answer multiple emails from the researcher or call the researcher back. A
Facebook and Instagram page was created to attract people to join the study, attracting 110 and
134 followers, respectively. The researcher also joined social media forums to build relationships
with epilepsy bloggers who had audiences consisting of thousands of followers. These
relationships led to researcher participation in an interview with a prominent epilepsy advocator
broadcasted on YouTube, which attracted 54 views across national and international audiences.
At this point, the researcher realized that a community of young people already had a forum to
share their stories and dialogue. With increasing exposure and visibility in the epilepsy online
community, epilepsy bloggers and advocators began advertising the study, thus generating more
interest, and attracting people. Interaction with these social platforms and people led to the
enrollment of 15 participants (Figure 8).
Recommendations: Researchers should be flexible and use various recruitment methods
such as social media platforms, community outreach, flyers, organizational and healthcare
provider collaboration that are trusted and have buy-in with participants.2-4
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Snowball Sampling
This traditional recruitment strategy has been reported as effective. 3 In this study,
participants recommended friends and caregivers to participate in the study. The researcher
enrolled five participants using this method (Figure 8).
Recommendations: Researchers should strive to build relationships with participants.
These relationships build trust and can result in referrals.2,3 Also, building rapport with social
media bloggers, advocators, and online groups can boost recruitment.2,3
Consent Template Language
The IRB consent related to using participants' identifiable and de-identified information
to create products or deliver services for commercial purposes resulted in 11 eligible participants
refusing to give verbal consent after preparing to enroll. All 11 voiced concerns about the
security or privacy of their personal information. The novice researcher revisited the verbiage
through the lens of a potential participant and recognized their concerns as valid. Comments
from some of these potential participants included: "I did not want my personal information out
there." "My mom felt uncomfortable for me to join the study." My personal information could be
used without my knowledge." "The university is making money, and I would not?"
Unquestionably, the phrasing of the consent had made these potential participants feel
uncomfortable, and their withdrawal greatly impacted the target sample size requirements
because recruitment goals were not met.3
Recommendations: Researchers should go over language with a discriminating eye for
any verbiage that could alarm potential participants. Researchers and their affiliated IRBs should
negotiate and re-evaluate terms or verbiage for specific populations, particularly those who may
have been marginalized, to tailor them accordingly.3 As this may entail a lengthy process, a pilot
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study of participant reactions would help guide and strengthen a rationale to the IRB for changes.
Perhaps most importantly, researchers should learn to read the consent document as study
participants to measure a sense of comfort with signing it. 2,3
Underrepresentation of Minorities
The National Institute of Health (NIH) Revitalization Act of 1993 "mandated that NIHfunded research must include minorities." 7 Despite using standard recruitment methods, the
sample of AYA who met eligibility was mostly Caucasian, college-educated, and involved in the
epilepsy community. The researcher could not reach or enroll people from different races for
unknown reasons (Figure 9).

Figure 9. Participant Demographic Information
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Recommendations: Researchers may need to familiarize themselves with approaches that
have successfully built rapport and trust with non-Caucasian stakeholders for intervention
studies. If trust is established with some community leaders (eg, through churches, schools,
councils), then harder-to-reach or more distrustful members from other racial or cultural
backgrounds may be easier to contact and enroll. Collaboration with organizations that have
available database analytic systems may also help with reaching specific demographics of
participants.2,3,5
Conclusion
Recruitment challenges and lessons were shared to help inform other researchers who
conduct interventional studies with vulnerable AYA populations. The standard template
language used in the IRB consent form greatly impacted the target recruitment goal for this
study. The most impactful lesson learned was that researchers should strive to place themselves
in participants' shoes and ask themselves, "Would I sign this consent?" Researchers'
collaboration with their respective IRBs in adapting consent language is warranted. The author
encourages the epilepsy community of researchers to share their challenges and experiences in
the spirit of advancing science.
Chapter Four References
1.

Centers for Disease Control and Prevention. Epilepsy. Updated October 26, 2020.
Accessed September 20, 2020. https://www.cdc.gov/epilepsy/index.html

2.

Mc Govern EM, Maillart E, Bourgninaud M, Manzato E, Guillonnet C, Mochel F,
Bourmaleau J, Lubetzki C, Baulac M, Roze E. Making a 'JUMP' from paediatric to adult

76

healthcare: A transitional program for young adults with chronic neurological disease.
Journal of the neurological sciences. 2018;395:77-83. doi:10.1016/j.jns.2018.09.030
3.

Sanders J, Munford R. Hidden in Plain View: Finding and Enhancing the Participation of
Marginalized Young People in Research. International journal of qualitative methods.
2017;16(1):160940691770476. doi:10.1177/1609406917704765

4.

UyBico SJ, Pavel S, Gross CP. Recruiting Vulnerable Populations into Research: A
Systematic Review of Recruitment Interventions. Journal of general internal medicine:
JGIM. 2007;22(6):852-863. doi:10.1007/s11606-007-0126-3

5.

Jones B, Woolfenden S, Pengilly S, Breen C, Cohn R, Biviano L, Johns A, Worth A,
Lamb R, Lingam R, Silove N, Marks S, Tzioumi D, Zwi K. COVID‐19 pandemic: The
impact on vulnerable children and young people in Australia. Journal of paediatrics and
child health. 2020;56(12):1851-1855. doi:10.1111/jpc.15169

6.

Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment
methods. Journal of multidisciplinary healthcare. 2016;9(1):211-217.
doi:10.2147/JMDH.S104807

7.

Burchard EG. Missing patients. Nature (London). 2014;513(7518):301-302.
doi:10.1038/513301a

77

APPENDIX A: TRAQ TOOL

78

79

APPENDIX B: MAUQ TOOL

80

81

82

APPENDIX C: RECRUITMENT FLYER

83

84

APPENDIX D: DOWN-TIME MEDICINE LOG

85

86

APPENDIX E: CRITERIA FOR MEASURE DEVELOPMENT

87

Instrument

Scientific Content Reliability
Need

Validity

Quantitative

Factor

Item Analysis

Analysis

Validity Clinical
Utility

Cost-

Translated

effectiveness

to Other
Languages

Subjective
MMAS

+

+

+

+

+

+

+

-

+

BMQ

+

+

+

+

+

+

+

-

+

PEMSQ

+

+

+

+

+

+

+

-

-

PESQ

+

+

+

+

+

+

+

-

-

AEMSQ

+

-

-

-

-

-

-

-

-

MEMS ™

+

+

+

+

+

+

+

-

-

Text-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

-

+

+

+

+

+

+

+

+

+

Objective

messaging
MEMS ™
and PESQ
MEMS ™
and PESQ
M-app

88

APPENDIX F: UCF IRB

89

90

91

92

93

94

95

96

